STOCKS TELEGRAPH

Tag: ReShape Life Sciences

  • ReShape Life Sciences (RSLS) Shifts Gears in the After Market Hours

    ReShape Life Sciences (NASDAQ: RSLS) has been a favorite in the market in recent days, bringing on triple-digit growth, that has brought benefits to many players in the market. Recent updates may suggest that things may be about to change soon for the stock.

    The RSLS Gains Hit the Ceiling.

    Following a staggering performance in the market in recent days which saw ReShape Life Sciences (RSLS) climb from $6 to as high as $28, the aftermarket traders during the weekend have been pursuing a corrective sell-off. During the after-hours market, RSLS has dropped by as much as 33%, yet despite this it continues to trade at almost $12, still keeping its gains at an impressive level. Considering that the mighty gains of recent days had come about with no apparent fundamental shift or company update, it makes sense as to why traders began pulling out of their positions and cashing out their gains of RSLS

    More Cause for Concern

    In addition to the sizeable price pump, market traders continue to hold hesitance regarding RSLS, due to some recent updates. Recently, ReShape management asked the SEC to take down two filings that it erroneously submitted. However, one filing remains in place which indicates that 1.2 million shares will be issued in the near-term future, which will come with a warrant to each holder. For a company with a market capitalization of barely $8 million, and a share price of above $20, this dilution could result in a substantial fall in its price. This may be the primary reason as to why the market has been shifting gears on RSLS stock.

    Conclusion

    RSLS stock has brought on an epic rise in recent days, but many factors suggest that its days of glory may well be behind it, moving forward. There are several concerns such as a possible share dilution, which may explain the after-market plunge the stock has been seeing lately.

  • ReShape Life Sciences (RSLS) Stock in Trouble

    ReShape Life Sciences Inc. (NASDAQ: RSLS) is a company specializing in medical equipment that is geared towards patients suffering from heart conditions and obesity to metabolic ailments. What was once a star performer with a presence in the US, Europe, Australia, and other international markets has fallen to deadly lows, with imminent challenges.

    Plummeting RSLS Share Price

    The stock for ReShape Life Sciences Inc. (RSLS) has had an awful year in 2022, which saw it fall from its glorious highs of above $70, down to a low of $5.40. This comes despite several noteworthy updates that had taken place in the last 12 months, including an FDA approval for its very own disposable Gastro Intestinal Balloon Indicator calibration tube. The impact of this, owing to its small demand, remains minuscule, relative to the wider performance of the company.

    Financial Challenges Mount on For ReShape Life Sciences

    The woes that RSLS currently faces can best hold reflected in the company’s business performance. In its most recent quarterly report, its revenue saw a contraction, year-on-year, by as much as 25%. This drop by $900,000 comes as the management attempts to shift to US markets and diverge focus away from the lucrative European markets. ReShape is clearly bearing the cost of this strategic miscalculation, yet maintains that the move will pay off in the coming years. Its existing pipeline holds no promising candidates as of yet, which places the company’s hopes at bleak levels. This explains the market’s wider pessimism surrounding RSLS.

    Conclusion

    RSLS is a stock that has performed terribly, owing to fragile fundamentals, and a losing grip on its market share due to strategic miscalculations. Shareholders are clearly facing panic as the market cap of the company seems to have fallen to dangerous lows, and is on the verge of dropping below $3 million. All signs show that delisting maybe soon.